FDA Speeds Up Eye Drug for Rare Kids' Disease with Magic Voucher
Published Date: 3/13/2026
Notice
Summary
The FDA just approved EYLEA HD (aflibercept) using a special Rare Pediatric Disease Priority Review Voucher, speeding up its review because it treats a rare childhood illness. This means the company behind EYLEA HD got a fast-track pass, helping kids get medicine sooner. Keep an eye out for more rare disease treatments moving faster thanks to this program!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Faster Approval for Rare Pediatric Drug
If you have a child with the rare pediatric condition treated by EYLEA HD, the FDA approved EYLEA HD (aflibercept) using a Rare Pediatric Disease Priority Review Voucher. The supplemental application was approved on November 19, 2025, and the voucher sped up the review so children can access the medicine sooner.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20085, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program
The FDA is asking for public feedback by November 2, 2026, on its Voluntary Improvement Program (VIP), which helps medical device makers improve quality through third-party reviews. This program supports better products and safer devices without adding extra costs or deadlines for companies. It’s all about encouraging excellence and teamwork between the FDA, industry, and partners like the Medical Device Innovation Consortium.
Previous / Next Documents
Previous: 2026-04887, Flixbus SE, Flix North America Inc., and Greyhound Lines, Inc.-Control-Pacific Northwest Bus LLC
Flixbus SE, Flix North America, and Greyhound are teaming up to keep control of a new bus company called Pacific Northwest Bus LLC. The government is giving a thumbs-up to this plan, as long as no one objects by April 27, 2026. This move helps these companies keep their bus services running smoothly in the Pacific Northwest without any hiccups.
Next: 2026-04891, Agency Information Collection Activities; Submission for OMB Review; Comment Request; Fidelity Bonding Issuance
The Department of Labor is asking for public feedback on its plan to collect info about fidelity bonds that protect employers hiring people who might have a tough time getting jobs. This includes folks like recovering addicts, youth without work history, and others. Comments are open until April 13, 2026, and the goal is to make sure the info collection is useful and not too much work for anyone involved.